U.S. pharma large copyright scrapped two experimental weight loss products last 12 months—a at the time-each day capsule, lotiglipron, as a consequence of elevated liver enzymes and a two times-every day capsule, danuglipron, as a result of robust Unintended effects—but CEO Albert Bourla has stated the company is set to “Participate in and ga